Clinical Research Directory
Browse clinical research sites, groups, and studies.
Efficacy and Safety of HS-10374 Compared to Placebo in Adults With Active Psoriatic Arthritis
Sponsor: Hansoh BioMedical R&D Company
Summary
This study has been designed to explore the clinical efficacy and safety of HS-10374 in the treatment of active psoriatic arthritis. Additionally, this study is to find the optimal dosing for the future clinical development of HS-10374.
Official title: A Randomized, Double-blind, Placebo- and Comparator-controlled, Multicenter, Phase 2 Trial to Assess the Efficacy and Safety of HS-10374 in Adults With Active Psoriatic Arthritis
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
160
Start Date
2024-02-26
Completion Date
2026-08-28
Last Updated
2024-07-18
Healthy Volunteers
No
Conditions
Interventions
HS-10374
Administered orally QD for 16 weeks
HS-10374-matched placebo tablets
Administered orally QD for 16 weeks
Tofacitinib 5Mg Tab,Oral
Administered orally BID for 16 weeks
Locations (1)
Huashan Hospital affiliated to Fudan University
Shanghai, Shanghai Municipality, China